BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been given a $5.00 price target by Roth Capital in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Roth Capital’s target price points to a potential upside of 106.61% from the company’s previous close.

Several other equities research analysts have also recently weighed in on BDSI. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Janney Montgomery Scott boosted their price objective on BioDelivery Sciences International from $3.00 to $4.00 and gave the stock a “fair value” rating in a research note on Monday, July 24th. HC Wainwright set a $4.00 price objective on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Monday, July 24th. Piper Jaffray Companies set a $4.00 price objective on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $4.50 price objective on shares of BioDelivery Sciences International in a research note on Monday, August 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. BioDelivery Sciences International currently has a consensus rating of “Buy” and an average target price of $4.29.

Shares of BioDelivery Sciences International (BDSI) opened at $2.42 on Monday. BioDelivery Sciences International has a twelve month low of $1.50 and a twelve month high of $3.60. The company has a current ratio of 1.28, a quick ratio of 1.07 and a debt-to-equity ratio of 1.89.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. The company had revenue of $11.25 million for the quarter, compared to analysts’ expectations of $9.40 million. During the same period in the previous year, the firm posted ($0.30) earnings per share. The firm’s revenue for the quarter was up 215.1% on a year-over-year basis. analysts predict that BioDelivery Sciences International will post 0.13 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “BioDelivery Sciences International, Inc. (BDSI) PT Set at $5.00 by Roth Capital” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/biodelivery-sciences-international-inc-bdsi-pt-set-at-5-00-by-roth-capital/1704137.html.

In other news, CEO Mark A. Sirgo sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $2.95, for a total transaction of $147,500.00. Following the transaction, the chief executive officer now owns 1,509,262 shares of the company’s stock, valued at $4,452,322.90. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Mark A. Sirgo sold 24,516 shares of the company’s stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $2.75, for a total value of $67,419.00. Following the transaction, the chief executive officer now directly owns 1,509,262 shares in the company, valued at approximately $4,150,470.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 402,127 shares of company stock worth $1,142,798. Insiders own 7.73% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BDSI. Royce & Associates LP bought a new position in shares of BioDelivery Sciences International during the third quarter valued at approximately $3,814,000. Blair William & Co. IL grew its stake in shares of BioDelivery Sciences International by 112.2% during the second quarter. Blair William & Co. IL now owns 1,471,122 shares of the specialty pharmaceutical company’s stock valued at $4,119,000 after buying an additional 777,941 shares during the last quarter. Stonepine Capital Management LLC grew its stake in shares of BioDelivery Sciences International by 22.2% during the second quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock valued at $9,737,000 after buying an additional 632,853 shares during the last quarter. EAM Investors LLC bought a new position in shares of BioDelivery Sciences International during the second quarter valued at approximately $1,348,000. Finally, Hikari Power Ltd grew its stake in shares of BioDelivery Sciences International by 127.2% during the second quarter. Hikari Power Ltd now owns 601,285 shares of the specialty pharmaceutical company’s stock valued at $1,684,000 after buying an additional 336,675 shares during the last quarter. 40.68% of the stock is currently owned by hedge funds and other institutional investors.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.